

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

SELF-DEVELOPED TMVR SYSTEM ACHIEVED EXCELLENT FOLLOW-UP RESULTS IN MULTIPLE CLINICAL APPLICATION CASES

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the transcatheter mitral valve replacement system (“**TMVR System**”) independently developed by the Group made progress with its clinical application and has been successfully used in the treatment of several patients with severe mitral regurgitation (“**MR**”), of which the first patient has recently completed one-year follow-up with positive results, while the three-month and one-month follow-up results of the other patients are also encouraging, all achieving significant MR reduction with no recurrence, no perivalvular leakage, no left ventricular outflow tract obstruction (“**LVOTO**”), and notable improvement of cardiac function-related indicators, all patients reported that the discomfort caused by MR had been significantly relieved. Our TMVR System is the world’s first dry-tissue TMVR product with clinical application, and its multiple successful in-man applications and excellent follow-up results further validated the effectiveness and safety of the system, marking a new phase in its clinical application.

The TMVR System applied the dry tissue technology independently developed by the Group for the first time, which shows better biocompatibility and anti-calcification properties, and facilitates preoperative preparation, storage and transportation. The simplicity in its prosthetic valve design greatly reduces the operational difficulty and the LVOTO risk, bringing excellent hemodynamic performance and solving technical issues in transcatheter mitral valve replacement (“**TMVR**”) procedures such as prosthetic valve anchoring and fixation. The TMVR System adopted the transapical approach in all previous clinical applications, the operation of which is simple and physician-friendly. In the several applications, the entry to withdrawal of the delivery system took only 15 minutes the shortest.

MR is one of the most common life-threatening heart valve diseases. TMVR, as a widely discussed interventional treatment for structural heart diseases in recent years, still presents many technical issues in its clinical applications. Based on our deep understanding and exploration of clinical pain points, we have accomplished several breakthroughs in key technologies and independently developed the TMVR System. The completion of multiple follow-ups of the TMVR System has once again demonstrated the Group's solid technical reserves and innovation capabilities in the field of structural heart diseases, further solidifying the foundation for the Group's comprehensive deployment in the field of structural heart diseases. We will accelerate the multi-center clinical applications of the TMVR System, and support its research and development process with more detailed medical evidence, so as to launch the product to the market as soon as possible, and address the global unmet needs of TMVR therapy.

There is no assurance that the Company will ultimately be able to successfully commercialize the TMVR System. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, August 6, 2023

As at the date of this announcement, the executive directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.